Department of Medical Physics, Center for Interdisciplinary Research, D.Y. Patil Education Society (Institution Deemed to be University), Kolhapur 416006, MS, India.
Department of Physics, Rajaram College, Kolhapur 416004, MS, India.
Drug Discov Today. 2021 Mar;26(3):724-739. doi: 10.1016/j.drudis.2020.12.016. Epub 2020 Dec 25.
Cancer cell resistance to chemotherapeutics (chemoresistance) poses a significant clinical challenge that oncology research seeks to understand and overcome. Multiple anticancer drugs and targeting agents can be incorporated in nanomedicines, in addition to different treatment modalities, forming a single nanoplatform that can be used to address tumor chemoresistance. Nanomedicine-driven molecular assemblies using nucleic acids, small interfering (si)RNAs, miRNAs, and aptamers in combination with stimuli-responsive therapy improve the pharmacokinetic (PK) profile of the drugs and enhance their accumulation in tumors and, thus, therapeutic outcomes. In this review, we highlight nanomedicine-driven molecular targeting and therapy combination used to improve the 3Rs (right place, right time, and right dose) for chemoresistant tumor therapies.
癌症细胞对化疗药物的耐药性（化疗耐药性）是肿瘤学研究试图理解和克服的一个重大临床挑战。多种抗癌药物和靶向药物可以与不同的治疗方式一起被纳入纳米药物中，形成一个可以用于解决肿瘤化疗耐药性的单一纳米平台。使用核酸、小干扰（si）RNA、miRNA 和适体的纳米医学驱动的分子组装与刺激响应治疗相结合，改善了药物的药代动力学（PK）特征，并增强了它们在肿瘤中的积累，从而提高了治疗效果。在这篇综述中，我们强调了纳米医学驱动的分子靶向和治疗联合应用，以改善化疗耐药性肿瘤治疗的 3R（正确的地点、正确的时间和正确的剂量）。
